Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases.
Standard
Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. / Nielsen, Peter; Fischer, Roland; Buggisch, Peter; Janka-Schaub, Gritta.
in: BRIT J HAEMATOL, Jahrgang 123, Nr. 5, 5, 2003, S. 952-953.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases.
AU - Nielsen, Peter
AU - Fischer, Roland
AU - Buggisch, Peter
AU - Janka-Schaub, Gritta
PY - 2003
Y1 - 2003
N2 - The treatment of iron overload by s.c. desferrioxamine (DFO) was studied in three patients with hereditary haemochromatosis in which phlebotomy treatment was not, or transiently not, possible because of their serious clinical condition or the lack of appropriate peripheral veins. Repeated non-invasive liver iron concentration measurements by superconducting quantum interference device biosusceptometry showed that DFO treatment (2 g/d for 9-11 months) was as effective (liver iron elimination rate: 12 mg/d) as normal phlebotomy treatment (5.9 or 14.3 mg/d respectively) with weekly 500-ml blood removals. This demonstrates that DFO is an effective alternative therapy for haemochromatosis when phlebotomy is not possible.
AB - The treatment of iron overload by s.c. desferrioxamine (DFO) was studied in three patients with hereditary haemochromatosis in which phlebotomy treatment was not, or transiently not, possible because of their serious clinical condition or the lack of appropriate peripheral veins. Repeated non-invasive liver iron concentration measurements by superconducting quantum interference device biosusceptometry showed that DFO treatment (2 g/d for 9-11 months) was as effective (liver iron elimination rate: 12 mg/d) as normal phlebotomy treatment (5.9 or 14.3 mg/d respectively) with weekly 500-ml blood removals. This demonstrates that DFO is an effective alternative therapy for haemochromatosis when phlebotomy is not possible.
M3 - SCORING: Zeitschriftenaufsatz
VL - 123
SP - 952
EP - 953
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 5
M1 - 5
ER -